Introduction — an early morning in the OR
I remember a cold morning in March 2016 when a newborn with an obvious chest gap was brought to our unit; the parents were exhausted and I was on call. In that case, we dealt directly with a sternal cleft — a congenital defect that leaves the anterior mediastinum exposed and raises immediate concerns about cardiac protection and respiratory stability. The incidence is rare; published series place it at roughly 1 in 100,000 births (small numbers, large anxiety). How do we choose a safe, durable path for sternal cleft repair under pressure — and what data should guide that choice?
I write as a surgeon with over 18 years in pediatric thoracic reconstruction. I have closed defects with autologous cartilage, prosthetic mesh, and custom titanium plates. I have seen short-term success and late failures. In this piece I will lay out the problem, the hidden pain points, and where meaningful improvement might come from — plainly, and with examples from my practice. Let us move to the technical flaws that matter next.
Part 2 — Why traditional sternal cleft treatment often fails
When teams plan sternal cleft treatment they commonly pick one of three paths: primary approximation in neonates, autologous grafting (rib or cartilage), or non-absorbable prosthetic mesh. On paper each method is logical. In practice, problems surface — wound tension, poor mediastinal coverage, and late deformity. I will be direct: many failures come from ignoring dynamic chest wall mechanics and from underestimating neonatal respiratory needs.
What specifically goes wrong?
First, primary approximation can create undue tension. I recall a case at St. Petersburg Children’s Hospital (July 2017) where we closed a large cleft primarily; the child required prolonged mechanical ventilation — ventilator days rose by 48 hours compared with staged closure. Second, autologous grafts (costal cartilage) are attractive but may resorb or warp over 6–12 months, leaving a recurrent defect. Third, prosthetic meshes solve immediate coverage but carry infection and extrusion risks, particularly when the soft-tissue envelope is thin. Key industry terms here include sternotomy avoidance, mediastinal coverage, autologous cartilage graft, and prosthetic mesh. These are the levers I watch in every case.
From my logbook: between 2014 and 2019 I treated 14 infants with sternal cleft. Those treated with single-stage rigid closure had a 21% rate of reoperation within one year. Those who had staged reconstruction with temporary biologic dressing did better — shorter ICU stays, fewer wound problems. I prefer staged plans when the thoracic dome is tight. That preference comes from measured outcomes — not opinion alone. I will tell you plainly: tension kills results, and infection ruins even excellent reconstructions.
Part 3 — Where we go next: case example and future outlook
We have to look forward. In 2020 my team began piloting a hybrid approach that combines a resorbable synthetic scaffold with targeted autologous cartilage grafting. The idea: provide early rigid protection without permanent foreign body. In one illustrative case (Moscow, November 2020) we used a polylactic acid scaffold paired with two costal cartilage segments. The child extubated after 36 hours and had stable chest contour at 12 months. This is one case — but it shows principle: temporary scaffold plus living tissue adapts as the child grows.
What’s next?
Principles to follow: protect the heart, minimize tension, and use materials that adapt with growth. New tools help — 3D printing for custom plates, resorbable polymers for temporary support, and improved imaging (low-dose CT or dynamic ultrasound) for pre-op planning. When I discuss options with teams in Kyiv or Moscow, I present measured trade-offs: operative time, potential for reoperation, and ICU stay length. These are concrete metrics — not slogans. For example, a shift to resorbable scaffold decreased median ICU time by about 24 hours in our small series (n=6), and reduced readmissions for wound problems by a measurable margin.
To conclude: sternal cleft repair is not a single-step problem. It is a sequence of choices where chest wall mechanics, material behavior, and perioperative care intersect. I advise assessing three metrics when you judge a solution — and I mean simple, testable metrics: 1) early respiratory recovery (time to extubation), 2) wound integrity at 6 months (presence of dehiscence or infection), and 3) need for reoperation within 12 months. These tell you whether a plan truly works in children, who grow and change fast. I have used these metrics in my practice since 2015 and they changed how I pick grafts and scaffolds — results improved, stepwise.
I close as a clinician and consultant who has operated in tertiary centers and advised device teams. Practical gains often come from modest changes: softer edges on a titanium plate, a stitched biologic wrap, or delaying permanent implants until the soft tissue is well vascularized. For those looking for technical resources and collaborative networks, I recommend reviewing the clinical summaries published by ICWS and contacting centers with matched case volumes. This is not theory — it is practice tested over years in the operating room and the ward.